Mavorixafor clinical trials
Also written X4P-001 and AMD11070.
How each study uses mavorixafor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mavorixafor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Apr 2024 · XOLREMDI · NDA 218709 (FDA, Drugs@FDA)
- European Union
- 27 Apr 2026 · Xolremdi · EMEA/H/C/006496 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2016 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2016 | 5 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 2
X4 Pharmaceuticals (12) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Genzyme, a Sanofi Company (1) · Abbisko Therapeutics Co, Ltd (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test mavorixafor, phase 3 first.
Studies
Open first, then newest update. How each study uses mavorixafor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious InfectionsRecruitingPhase 3X4 PharmaceuticalsNCT06056297Written as Mavorixafor
- A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia DisordersNot yet recruitingPhase 2X4 PharmaceuticalsNCT07902830Written as Mavorixafor
- A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic FunctionCompletedPhase 1X4 PharmaceuticalsNCT06858696Written as Mavorixafor
- Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeCompletedPhase 3X4 PharmaceuticalsNCT03995108Written as Mavorixafor
- A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia DisordersCompletedPhase 1/2X4 PharmaceuticalsNCT04154488Written as Mavorixafor
- Drug-Drug Interaction Potential of MavorixaforCompletedPhase 1X4 PharmaceuticalsNCT06914869Written as Mavorixafor
- A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeCompletedPhase 2X4 PharmaceuticalsNCT03005327Written as X4P-001
- Trial of X4P-001 in Participants With Advanced Renal Cell CarcinomaCompletedPhase 1/2X4 PharmaceuticalsNCT02667886Written as X4P-001
- A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4CompletedPhase 1X4 PharmaceuticalsNCT04274738Written as Mavorixafor
- Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell CarcinomaTerminatedPhase 1/2X4 PharmaceuticalsNCT02923531Written as X4P-001
- Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected PatientsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00089466Written as AMD11070
- A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBCStatus unknownPhase 1/2Abbisko Therapeutics Co, LtdNCT05103917Written as X4P-001
- Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected MenCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00063804Written as AMD070
- X4P-001 and Pembrolizumab in Patients With Advanced MelanomaCompletedPhase 1X4 PharmaceuticalsNCT02823405Written as X4P-001
- A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy VolunteersTerminatedPhase 1X4 PharmaceuticalsNCT02680782Written as X4P-001
- A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic VirusCompletedPhase 1Genzyme, a Sanofi CompanyNCT00361101Written as AMD11070
What changed recently
From the registry's own updates since Oct 18, 2026.
Codes
What other systems call mavorixafor · ClinicalTrials.gg INT004728
- MeSH (NLM) C494414mavorixaforConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0G9LGB5O2WMAVORIXAFORConfirmed FDA, NLM, Wikidata
- Wikidata Q27074430mavorixaforConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C126660MavorixaforOne source FDA
- DrugBank DB05501One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C494414 | mavorixafor | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0G9LGB5O2W | MAVORIXAFOR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27074430 | mavorixafor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C126660 | Mavorixafor | One source FDA |
| DrugBank | DB05501 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.